The findings indicate that the mechanisms by which PACAP induces migraine are independent of CGRP, meaning its potential to be an alternative therapeutic target for migraine patients who have a poor response to anti-CGRP therapy [18, 19]. The gene discussed is ADCYAP1; the disease is migraine disorder.